VOB560-MIK665 Combination First in Human Trial in Patients With Hematological Malignancies (Relapsed/Refractory Non-Hodgkin Lymphoma, Relapsed/Refractory Acute Myeloid Leukemia, or Relapsed/Refractory Multiple Myeloma)
Summary
Third Opinion Trial Synopsis:
This study wants to find out if a combination of drugs called VOB560 and MIK665 can help treat Non-Hodgkin lymphoma, Multiple Myeloma, and Acute Myeloid Leukemia. These drugs block proteins that help tumor cells stay alive, so they could make the tumor cells die instead. Previous tests showed that using the drugs together was effective against tumors. The study is also looking to see how much of the drugs can be given safely.
This study wants to find out if a combination of drugs called VOB560 and MIK665 can help treat Non-Hodgkin lymphoma, Multiple Myeloma, and Acute Myeloid Leukemia. These drugs block proteins that help tumor cells stay alive, so they could make the tumor cells die instead. Previous tests showed that using the drugs together was effective against tumors. The study is also looking to see how much of the drugs can be given safely.
*Third Opinion AI Generated Synopsis
Trial Summary
The purpose of the study is to identify doses and schedules of VOB560 and MIK665 that can be safely given and to learn if the combination can have possible benefits for patients with Non-Hodgkin lymphoma (NHL), Multiple Myeloma (MM) or Acute Myeloid Leukemia (AML). VOB560 and MIK665 are selective and potent blockers respectively of the B-cell lymphoma 2 (BCL2) protein and of the myeloid cell leukaemia 1 (MCL1) protein, proteins that may protect tumor cells from undergoing cell death. VOB560 and MIK665 are designed to block the functions of the BCL2 and MCL1 proteins, so that the tumor cells that rely on these proteins undergo cell death. Preclinical data suggest that concomitant treatment with VOB560 in combination with MIK665 induces robust anti-tumor activity.
The purpose of the study is to identify doses and schedules of VOB560 and MIK665 that can be safely given and to learn if the combination can have possible benefits for patients with Non-Hodgkin lymphoma (NHL), Multiple Myeloma (MM) or Acute Myeloid Leukemia (AML). VOB560 and MIK665 are selective and potent blockers respectively of the B-cell lymphoma 2 (BCL2) protein and of the myeloid cell leukaemia 1 (MCL1) protein, proteins that may protect tumor cells from undergoing cell death. VOB560 and MIK665 are designed to block the functions of the BCL2 and MCL1 proteins, so that the tumor cells that rely on these proteins undergo cell death. Preclinical data suggest that concomitant treatment with VOB560 in combination with MIK665 induces robust anti-tumor activity.
Locations & Contact
Fill out the form and "Notify Multiple Myeloma Research Foundation" to let the Multiple Myeloma Research Foundation know you are interested in this trial.